Dhansa Labs schedules Q4FY26 earnings call on June 5

1 min read     Updated on 03 Jun 2026, 08:42 AM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Dhansa Labs Limited announced its Q4FY26 earnings conference call scheduled for June 5, 2026, at 5:00 PM IST. The call will cover financial results for the quarter and year ended March 31, 2026, with Chairman Mr. Arcchit Gupta leading the discussion.

powered bylight_fuzz_icon
42001936

*this image is generated using AI for illustrative purposes only.

Dhansa Labs Limited will conduct an earnings conference call on June 5, 2026, to discuss its financial performance for the quarter and year ended March 31, 2026. The meeting is scheduled to begin at 5:00 PM IST and will include a presentation of the Q4FY26 results followed by an interactive question and answer session with the management.

The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. Ambey Laboratories , formerly known as Dhansa Labs Limited, has provided specific dial-in access numbers and registration details for participants wishing to join the discussion.

Conference Call Details

The company has outlined the logistics for the call, including separate access routes for registered and non-registered participants. International attendees have been provided with a specific Participant PIN for connectivity.

Access Type Details
Date Friday, June 5, 2026
Time 05:00 PM IST
Dial-in Numbers 086 3416 8767, 086 4536 6880
International PIN 7651981#
Registration Link Available on the company website

Participants are advised to dial in approximately 10 minutes prior to the scheduled start time to ensure timely connection. Registered participants can use the Diamond Pass registration link to receive call details via email, while non-registered participants will be connected by an operator after verification.

Management Representation

The session will feature key members of the company's leadership. Mr. Arcchit Gupta, Chairman and Whole-time Director, will be present to address the financial results and answer queries from analysts and investors.

The company has noted that certain statements made during the conference call may be forward-looking and subject to risks and uncertainties, including changes in the economic environment and government policies. Dhansa Labs Limited has stated that it does not provide any warranty regarding the accuracy or completeness of such forward-looking information.

Historical Stock Returns for Dhansa Labs

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-7.41%-24.59%-44.51%-35.48%-71.99%

What are the key financial metrics analysts should focus on during the Q4FY26 earnings presentation?

How might the recent rebranding from Dhansa Labs to Ambey Laboratories influence investor perception?

What strategic initiatives or growth drivers does the company plan to highlight during the Q&A session?

Dhansa Labs FY26 net profit rises 19.8% to ₹573.26 lakh

1 min read     Updated on 02 Jun 2026, 10:22 AM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Dhansa Labs reported a 19.8% rise in standalone net profit to ₹573.26 lakh for FY26, with revenue increasing 7.8% to ₹14,153.72 lakh. The board approved audited results, and the company allotted convertible equity warrants worth ₹4,999.99 lakh, utilizing ₹1,697.50 lakh received for corporate and capital expenditure purposes.

powered bylight_fuzz_icon
41374382

*this image is generated using AI for illustrative purposes only.

Dhansa Labs Limited reported a 19.8% increase in standalone net profit to ₹573.26 lakh for the financial year ended March 31, 2026, compared to ₹478.26 lakh in the previous year. Revenue from operations rose 7.8% to ₹14,153.72 lakh from ₹13,126.99 lakh in FY25. The Board of Directors approved the audited standalone and consolidated financial results for the quarter, half year, and financial year ended March 31, 2026, at a meeting held on May 29, 2026.

Financial Performance

The company’s basic earnings per share (EPS) for FY26 stood at ₹2.30, up from ₹2.06 in the previous year. For the quarter ended March 31, 2026, net profit was ₹208.94 lakh, while revenue from operations was ₹4,053.73 lakh. Total income for the year increased to ₹14,305.02 lakh from ₹13,318.60 lakh in the prior year. The finance cost for the six months ended March 31, 2026, was reduced by ₹58.94 lakh due to the reversal of costs previously recognized that should have been capitalised.

Capital Allocation and Warrants

During FY26, the company allotted 1,08,69,565 convertible equity warrants on a preferential basis at an issue price of ₹46 per warrant, aggregating to ₹4,999.99 lakh. The company received ₹1,697.50 lakh towards warrant subscription as of March 31, 2026. These funds were fully utilized for general corporate purposes, advances for plant and machinery, supporting ongoing capital expenditure, and land-related advances. There was no deviation in the utilization of funds raised.

Auditor’s Report and Compliance

Statutory auditors M/s Kapish Jain & Associates issued an audit report with an unmodified opinion on the audited financial results. The company also disclosed that it assessed the impact of the New Labour Codes, effective from November 21, 2025, and recognized an incremental liability of ₹9.46 lakh pertaining to gratuity and leave encashment within employee benefit expenses. The consolidated financial results include the performance of subsidiaries Dhansa Green Energy Private Limited and Dhansa Biofuels Power Private Limited.

Metric FY26 (₹ in Lakhs) FY25 (₹ in Lakhs)
Revenue from operations 14,153.72 13,126.99
Total income 14,305.02 13,318.60
Total expenses 13,544.39 12,714.77
Net profit 573.26 478.26
Basic EPS (₹) 2.30 2.06

Historical Stock Returns for Dhansa Labs

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%-7.41%-24.59%-44.51%-35.48%-71.99%

How will the remaining subscription amount for the convertible equity warrants impact the company's equity dilution and capital structure in the coming year?

What specific capital expenditure projects are prioritized for the land and plant machinery advances funded by the recent warrant issuance?

How will the implementation of the New Labour Codes affect long-term operating costs beyond the current recognized liability?

More News on Ambey Laboratories

1 Year Returns:-35.48%